Allogene Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALLO and other ETFs, options, and stocks.

About ALLO

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. 

CEO
Zachary Roberts, MD, PhD
CEOZachary Roberts, MD, PhD
Employees
152
Employees152
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2017
Founded2017
Employees
152
Employees152

ALLO Key Statistics

Market cap
707.96M
Market cap707.96M
Price-Earnings ratio
-3.08
Price-Earnings ratio-3.08
Dividend yield
Dividend yield
Average volume
4.98M
Average volume4.98M
High today
$2.08
High today$2.08
Low today
$1.92
Low today$1.92
Open price
$1.97
Open price$1.97
Volume
4.61M
Volume4.61M
52 Week high
$4.46
52 Week high$4.46
52 Week low
$1.03
52 Week low$1.03

Stock Snapshot

Allogene Therapeutics(ALLO) stock is priced at $2.06, giving the company a market capitalization of 707.96M. It carries a P/E multiple of -3.08.

During the trading session on 2026-08-15, Allogene Therapeutics(ALLO) shares reached a daily high of $2.08 and a low of $1.92. At a current price of $2.06, the stock is +7.3% higher than the low and still -1.0% under the high.

Trading volume for Allogene Therapeutics(ALLO) stock has reached 4.61M, versus its average volume of 4.98M.

The stock's 52-week range extends from a low of $1.03 to a high of $4.46.

The stock's 52-week range extends from a low of $1.03 to a high of $4.46.

ALLO News

Investing.com 3d
Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast - Investing.com

...

Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast - Investing.com

Analyst ratings

91%

of 11 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

People also own

Based on the portfolios of people who own ALLO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.